コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
2 ations that allow accommodation of fucose in blood group B active GH110 enzymes or, in the case of Pd
3 Escherichia coli O86 possesses high human blood group B activity because of its O-antigen structur
4 ipients of allograft expressing incompatible blood group B also produce anti-Gal B antibody, which bi
7 ng kidneys from A2 donors into patients with blood group B and O recipients has been used to alleviat
8 explanation for contrasts in associations of blood groups B and AB between CagA-endemic and -nonendem
11 d to a series of oligomannose compounds, the blood group B antigen, and a fragment of beta-glucan rev
13 minant alpha1,3-linked galactose residues of blood group B antigens, we recently identified a novel p
15 have increased the transplantation rate for blood group B cadaveric waiting list candidates by trans
18 specificity of anti-alphaGal antibodies; (3) blood group B human and baboon sera have lower levels of
23 the criteria mentioned below is present), of blood group B or O, and with diabetes are most at risk i
24 The median waiting times for patients with blood groups B or O were 1329 and 1007 days, respectivel
26 his binding preference, Gal-9 readily killed blood group B-positive Escherichia coli, whereas Gal-9N
30 e carbohydrate binding properties, including blood group B-specific agglutination and preferential bi
32 isite substrate specificity for the branched blood group B structure Galalpha1-3(Fucalpha1-2)Gal, whe
33 have exclusive specificity for the branched blood group B structures, whereas members of a newly ide
36 Moreover, we found that the genetic-inferred blood group B was associated with a decreased risk (OR =